Key result
ASA intake is linked to more surgical interventions, higher recurrence, and increased epistaxis severity.
Why the study?
Acetylsalicylic acid contributes to nosebleeds by impairing thrombocyte aggregation, but its influence on the severity of epistaxis compared to other risk factors was unclear.
Does acetylsalicylic acid intake increase the severity of epistaxis in patients presenting to an ENT department?
Cohort (n=591)
No
Does acetylsalicylic acid intake increase the severity of epistaxis in patients presenting to an ENT department?
Acetylsalicylic acid intake is a major risk factor for severe epistaxis, leading to more surgical interventions and higher recurrence rates, highlighting the need for careful indication of antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
ASA use may heighten epistaxis severity and interventions; leaves open whether antiplatelet adjustment improves outcomes.
Soyka et al. (2009) conducted a cohort in Epistaxis (n=591). Acetylsalicylic acid (ASA) vs. No ASA intake was evaluated on Severity of epistaxis (surgical interventions, length of in-hospital stay, recurrences, number of treatments, severity score). Acetylsalicylic acid intake (present in nearly 30% of patients) was significantly associated with more surgical interventions, a higher recurrence rate, and an increased severity score.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: